{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:09:23Z","timestamp":1791403763600,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1124\/jpet.106.101618","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T00:40:00Z","timestamp":1146184800000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease"],"prefix":"10.1016","volume":"318","author":[{"given":"Dorota","family":"Zolkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.101618_bib1","doi-asserted-by":"crossref","unstructured":"Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasic JR, and Wong DF (2005) Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 56: 94-99.","DOI":"10.1002\/syn.20126"},{"key":"10.1124\/jpet.106.101618_bib2","doi-asserted-by":"crossref","unstructured":"Artigas F, Sarrias MJ, Martinez E, Gelpi E, Alvarez E, and Udina C (1989) Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl) 99: 328-332.","DOI":"10.1007\/BF00445552"},{"key":"10.1124\/jpet.106.101618_bib3","doi-asserted-by":"crossref","unstructured":"Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, and Rothman RB (2000) Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36: 102-113.","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#"},{"key":"10.1124\/jpet.106.101618_bib4","doi-asserted-by":"crossref","unstructured":"Baumann MH, Ayestas MA, Dersch CM, and Rothman RB (2001) 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24: 492-501.","DOI":"10.1016\/S0893-133X(00)00221-9"},{"key":"10.1124\/jpet.106.101618_bib5","doi-asserted-by":"crossref","unstructured":"Berger UV, Gu XF, and Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215: 153-160.","DOI":"10.1016\/0014-2999(92)90023-W"},{"key":"10.1124\/jpet.106.101618_bib6","doi-asserted-by":"crossref","unstructured":"Celada P, Dolera M, Alvarez E, and Artigas F (1992a) Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 25: 243-249.","DOI":"10.1016\/0165-0327(92)90082-H"},{"key":"10.1124\/jpet.106.101618_bib7","doi-asserted-by":"crossref","unstructured":"Celada P, Martin F, and Artigas F (1994) Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 55: 1237-1243.","DOI":"10.1016\/0024-3205(94)00663-6"},{"key":"10.1124\/jpet.106.101618_bib8","doi-asserted-by":"crossref","unstructured":"Celada P, Perez J, Alvarez E, and Artigas F (1992b) Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J Clin Psychopharmacol 12: 309-315.","DOI":"10.1097\/00004714-199210000-00003"},{"key":"10.1124\/jpet.106.101618_bib9","doi-asserted-by":"crossref","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337: 581-588.","DOI":"10.1056\/NEJM199708283370901"},{"key":"10.1124\/jpet.106.101618_bib10","doi-asserted-by":"crossref","unstructured":"Cooper JR, Bloom F, and Roth RH (2003) The Biochemical Basis of Neuropharmacology, 8th ed, Oxford University Press, New York.","DOI":"10.1093\/oso\/9780195140071.001.0001"},{"key":"10.1124\/jpet.106.101618_bib11","doi-asserted-by":"crossref","unstructured":"Cortijo J, Marti-Cabrera M, Bernabeu E, Domenech T, Bou J, Fernandez AG, Beleta J, Palacios JM, and Morcillo EJ (1997) Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol 122: 1455-1463.","DOI":"10.1038\/sj.bjp.0701509"},{"key":"10.1124\/jpet.106.101618_bib12","doi-asserted-by":"crossref","unstructured":"Crespi D, Mennini T, and Gobbi M (1997) Carrier-dependent and Ca2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121: 1735-1743.","DOI":"10.1038\/sj.bjp.0701325"},{"key":"10.1124\/jpet.106.101618_bib13","doi-asserted-by":"crossref","unstructured":"de Jong TR, Veening JG, Waldinger MD, Cools AR, and Olivier B (2006) Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev, in press.","DOI":"10.1016\/j.neubiorev.2006.01.001"},{"key":"10.1124\/jpet.106.101618_bib14","doi-asserted-by":"crossref","unstructured":"Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, and Adnot S (1999) Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: relationship with the mitogenic action of serotonin. Circ Res 84: 329-336.","DOI":"10.1161\/01.RES.84.3.329"},{"key":"10.1124\/jpet.106.101618_bib15","doi-asserted-by":"crossref","unstructured":"Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, and Adnot S (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Investig 108: 1141-1150.","DOI":"10.1172\/JCI12805"},{"key":"10.1124\/jpet.106.101618_bib16","doi-asserted-by":"crossref","unstructured":"Eddahibi S, Raffestin B, Hamon M, and Adnot S (2002) Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 139: 194-201.","DOI":"10.1067\/mlc.2002.122181"},{"key":"10.1124\/jpet.106.101618_bib17","doi-asserted-by":"crossref","unstructured":"Fishman AP (1999) Aminorex to fen\/phen: an epidemic foretold. Circulation 99: 156-161.","DOI":"10.1161\/01.CIR.99.1.156"},{"key":"10.1124\/jpet.106.101618_bib18","doi-asserted-by":"crossref","unstructured":"Gershon MD (2004) Review article: serotonin receptors and transporters: roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20 (Suppl 7): 3-14.","DOI":"10.1111\/j.1365-2036.2004.02180.x"},{"key":"10.1124\/jpet.106.101618_bib19","unstructured":"Hafizi S, Taylor PM, Chester AH, Allen SP, and Yacoub MH (2000) Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. J Heart Valve Dis 9: 454-458."},{"key":"10.1124\/jpet.106.101618_bib20","doi-asserted-by":"crossref","unstructured":"Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, and Drouet L (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254.","DOI":"10.1016\/S0002-9343(99)80156-9"},{"key":"10.1124\/jpet.106.101618_bib21","doi-asserted-by":"crossref","unstructured":"Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, and Levy RJ (2002) Serotonin mechanisms in heart valve disease: I. Serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161: 2111-2121.","DOI":"10.1016\/S0002-9440(10)64489-6"},{"key":"10.1124\/jpet.106.101618_bib22","doi-asserted-by":"crossref","unstructured":"Kilpatrick IC, Traut M, and Heal DJ (2001) Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord 25: 1454-1458.","DOI":"10.1038\/sj.ijo.0801732"},{"key":"10.1124\/jpet.106.101618_bib23","doi-asserted-by":"crossref","unstructured":"Lesch KP, Wolozin BL, Murphy DL, and Reiderer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319-2322.","DOI":"10.1111\/j.1471-4159.1993.tb03522.x"},{"key":"10.1124\/jpet.106.101618_bib24","doi-asserted-by":"crossref","unstructured":"MacLean MR, Herve P, Eddahibi S, and Adnot S (2000) 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131: 161-168.","DOI":"10.1038\/sj.bjp.0703570"},{"key":"10.1124\/jpet.106.101618_bib25","doi-asserted-by":"crossref","unstructured":"Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, and Eddahibi S (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168: 487-493.","DOI":"10.1164\/rccm.200210-1212OC"},{"key":"10.1124\/jpet.106.101618_bib26","doi-asserted-by":"crossref","unstructured":"Martin F and Artigas F (1992) Simultaneous effects of p-chloroamphetamine, d-fenfluramine and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 59: 1138-1144.","DOI":"10.1111\/j.1471-4159.1992.tb08356.x"},{"key":"10.1124\/jpet.106.101618_bib27","doi-asserted-by":"crossref","unstructured":"Morecroft I, Heeley RP, Prentice HM, Kirk A, and MacLean MR (1999) 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128: 730-734.","DOI":"10.1038\/sj.bjp.0702841"},{"key":"10.1124\/jpet.106.101618_bib28","doi-asserted-by":"crossref","unstructured":"Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, and Davies P (1994) Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am J Physiol 266: L178-L186.","DOI":"10.1152\/ajplung.1994.266.2.L178"},{"key":"10.1124\/jpet.106.101618_bib29","unstructured":"Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, Tajik J, and Schwartz RS (2001) Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10: 827-831."},{"key":"10.1124\/jpet.106.101618_bib30","doi-asserted-by":"crossref","unstructured":"Raleigh MJ, Brammer GL, Ritvo ER, Geller E, McGuire MT, and Yuwiler A (1986) Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites and behavior in monkeys. Psychopharmacology (Berl) 90: 503-508.","DOI":"10.1007\/BF00174069"},{"key":"10.1124\/jpet.106.101618_bib31","doi-asserted-by":"crossref","unstructured":"Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, and Feldman JM (1995) Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92: 790-795.","DOI":"10.1161\/01.CIR.92.4.790"},{"key":"10.1124\/jpet.106.101618_bib32","doi-asserted-by":"crossref","unstructured":"Rothman RB, Ayestas MA, Dersch CM, and Baumann MH (1999) Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 100: 869-875.","DOI":"10.1161\/01.CIR.100.8.869"},{"key":"10.1124\/jpet.106.101618_bib33","doi-asserted-by":"crossref","unstructured":"Rothman RB and Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40.","DOI":"10.1016\/j.ejphar.2003.08.054"},{"key":"10.1124\/jpet.106.101618_bib34","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3"},{"key":"10.1124\/jpet.106.101618_bib35","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000a) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"10.1124\/jpet.106.101618_bib36","doi-asserted-by":"crossref","unstructured":"Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313: 1361-1369.","DOI":"10.1124\/jpet.104.082503"},{"key":"10.1124\/jpet.106.101618_bib37","doi-asserted-by":"crossref","unstructured":"Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, and Bantle JP (2000b) Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 85: 913-915, A910.","DOI":"10.1016\/S0002-9149(99)00896-6"},{"key":"10.1124\/jpet.106.101618_bib38","doi-asserted-by":"crossref","unstructured":"Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, and Rudnick G (1993) Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 44: 1227-1231.","DOI":"10.1016\/S0026-895X(25)13357-9"},{"key":"10.1124\/jpet.106.101618_bib39","doi-asserted-by":"crossref","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63: 1223-1229.","DOI":"10.1124\/mol.63.6.1223"},{"key":"10.1124\/jpet.106.101618_bib40","doi-asserted-by":"crossref","unstructured":"Setola V and Roth BL (2005) Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on \u201cfen-phen.\u201d Expert Opin Drug Metab Toxicol 1: 377-387.","DOI":"10.1517\/17425255.1.3.377"},{"key":"10.1124\/jpet.106.101618_bib41","doi-asserted-by":"crossref","unstructured":"Ulus IH, Maher TJ, and Wurtman RJ (2000) Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 59: 1611-1621.","DOI":"10.1016\/S0006-2952(00)00306-3"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524328241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524328241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.101618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:57:09Z","timestamp":1740002229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524328241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0022356524328241"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.101618","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.101618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}